PT - JOURNAL ARTICLE AU - Monika Halicka AU - Axel D. Vittersø AU - Hayley McCullough AU - Andreas Goebel AU - Leila Heelas AU - Michael J. Proulx AU - Janet H. Bultitude TI - Prism adaptation treatment for upper-limb Complex Regional Pain Syndrome: a double-blind randomized controlled trial AID - 10.1101/2020.03.18.20038109 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.18.20038109 4099 - http://medrxiv.org/content/early/2020/03/20/2020.03.18.20038109.short 4100 - http://medrxiv.org/content/early/2020/03/20/2020.03.18.20038109.full AB - Initial evidence suggested that people with Complex Regional Pain Syndrome (CRPS) have reduced attention to the affected side of their body and the surrounding space, which might be related to pain and other clinical symptoms. Three previous unblinded, uncontrolled studies showed pain relief following treatment with prism adaptation, an intervention that has been used to counter lateralised attention bias in brain-lesioned patients. To provide a robust test of its effectiveness for CRPS, we conducted a double-blind randomized controlled trial of prism adaptation for unilateral upper-limb CRPS-I. Forty-nine eligible adults with CRPS were randomized to undergo two-weeks of twice-daily home-based prism adaptation treatment (n = 23) or sham treatment (n = 26). Outcomes were assessed in person four weeks prior to and immediately before treatment, and immediately after and four weeks post-treatment. Long-term postal follow-ups were conducted three and six months after treatment. We examined the effects of prism adaptation versus sham treatment on current pain intensity and CRPS symptom severity score (primary outcomes); as well as sensory, motor, and autonomic functions, self-reported psychological functioning, and experimentally tested neuropsychological functions (secondary outcomes). Primary and secondary outcomes did not differ between the prism adaptation and sham treatment groups when tested at either time point following treatment. Overall, CRPS severity significantly decreased over time for both groups, but we found no benefits of prism adaptation beyond sham treatment. Our findings do not support the efficacy of prism adaptation treatment for relieving upper-limb CRPS-I. This trial was prospectively registered (ISRCTN46828292).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN46828292Funding StatementThe study was supported by a grant from the Reflex Sympathetic Dystrophy Syndrome Association (RSDSA) awarded to JHB and MJP. The RSDSA approved the design of the study. MH and ADV were supported by studentships from the University of Bath and the GW4 Medical Research Council BioMed Doctoral Training Partnership (ref. 1793344), respectively. HM and AG have received support from the Pain Relief Foundation, Liverpool. The funders had no role in data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData supporting this manuscript will be made available on Open Science Framework upon acceptance of the manuscript for publication.